Bio Pharma Dive
DECEMBER 6, 2023
The deal hands AbbVie a portfolio of psychiatric medicines that originated within Pfizer, among them a closely watched schizophrenia treatment that’s in late-stage testing.
Pharmaceutical Technology
DECEMBER 6, 2023
Seattle Children's launched BrainChild Bio to focus on expediting the development of CAR T-cell therapies in central nervous system tumours.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Bio Pharma Dive
DECEMBER 6, 2023
The pharma is developing Fabhalta, now cleared for paroxysmal nocturnal hemoglobinuria, for several other rare, complement-driven diseases.
Pharmaceutical Technology
DECEMBER 6, 2023
IGM will lay off 22% of its staff and suspend four clinical activities to advance autoimmune diseases and colorectal cancer programmes.
Bio Pharma Dive
DECEMBER 6, 2023
Data collected by the research firm suggests venture funding totals are still sliding amid a "strategic shift" by investors towards fewer, but more substantial deals.
Rethinking Clinical Trials
DECEMBER 6, 2023
In this Friday's PCT Grand Rounds, Ruth Engelberg, Erin Kross, and Robert Lee of the University of Washington will present "A Pragmatic Randomized Trial of the Jumpstart Intervention to Promote Communication About Goals of Care for Hospitalized Patients With Serious Illness." The Grand Rounds session will be held on Friday, December 8, 2023, at 1:00 pm eastern.
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
Pharma Mirror
DECEMBER 6, 2023
Oral health is a critical component of overall well-being, and growing research suggests that the health of your mouth is closely connected to your body’s overall health. The mouth serves as a gateway to the body, and any issues or infections that begin in the oral cavity can impact other systems and organs. We will explore the intricate relationship between oral health and overall body health, shedding light on how taking care of your teeth and gums can benefit your well-being.
Bio Pharma Dive
DECEMBER 6, 2023
The results dim the outlook of so-called BTK inhibitors as potential autoimmune disease treatments and could have ramifications for Roche, Sanofi and Novartis.
Pharmaceutical Technology
DECEMBER 6, 2023
Odyssey Therapeutics, a biotechnology company developing immunomodulators and oncology therapy, has secured $101m in a Series C funding round.
Bio Pharma Dive
DECEMBER 6, 2023
The company moved quickly to capitalize on the stock surge, announcing plans to raise $300 million through a secondary stock offering.
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
Pharmaceutical Technology
DECEMBER 6, 2023
Health Canada has granted expanded authorisation for Novavax’s updated Covid-19 vaccine, Nuvaxovid XBB.1.5.
Rethinking Clinical Trials
DECEMBER 6, 2023
Speaker James P. Hughes, PhD Professor Emeritus of Biostatistics, University of Washington Slides Keywords Design, Analysis, Stepped-Wedge Trial Key Points Stepped-wedge design is typically run by clusters that are randomized. Each of the clusters receive the control and treatment, and each cluster is sequenced to the intervention at different times.
Pharmaceutical Technology
DECEMBER 6, 2023
AbbVie will pay $30m upfront and up to approximately $325m in milestone-based payments for treatments in neuroscience and oncology.
BioSpace
DECEMBER 6, 2023
A combination of Merck’s experimental anti-TIGIT antibody vibostolimab and anti-PD-1 drug Keytruda failed to hit its endpoints in a mid-stage non-small cell lung cancer study.
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
Pharmaceutical Technology
DECEMBER 6, 2023
The Phase Ib trial will evaluate the combination therapy of Welireg and HC-7366 in patients with clear cell renal cell carcinoma.
Fierce Pharma
DECEMBER 6, 2023
With an FDA approval in PNH, Novartis has gained its first nod for iptacopan, dubbed two months ago “a pipeline in pill," by analysts at ODDO BHF.
Pharmaceutical Technology
DECEMBER 6, 2023
Tislelizumab is under clinical development by BeiGene and currently in Phase III for Gastroesophageal (GE) Junction Carcinomas.
Pharma Times
DECEMBER 6, 2023
The neurological condition currently affects one in 300 people in the UK - News - PharmaTimes
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
Pharmaceutical Technology
DECEMBER 6, 2023
The US FDA has accepted Bristol Myers Squibb’s sBLA for Opdivo plus cisplatin-based chemotherapy as a first-line treatment
Drug Discovery World
DECEMBER 6, 2023
Osteoarthritis may be treatable and reversible, according to a new University of Adelaide study. The researchers have discovered a novel population of stem cells – marked by the Gremlin 1 gene – responsible for the progression of osteoarthritis. Treatment with fibroblast growth factor 18 (FGF18) stimulated the proliferation of Gremlin 1 cells in joint cartilage in mice, leading to significant recovery of cartilage thickness and reduced osteoarthritis.
Pharmaceutical Technology
DECEMBER 6, 2023
CG Oncology has received fast track designation and breakthrough designation needed to accelerate US FDA submission.
BioSpace
DECEMBER 6, 2023
The deal, announced late Wednesday, will provide AbbVie with access to Cerevel Therapeutics’ pipeline of clinical-stage and preclinical candidates for psychiatric and neurological diseases.
Advertisement
When selecting a clinical supply provider, consideration often focuses upon the manufacturing, packaging, storage and distribution capabilities available that will, at face-value, be sufficient to meet the needs of the sponsor and their trial. However, there are human-based and knowledge-driven factors that are often overlooked that go beyond these basic physical capabilities and are integral to the development and delivery of high performing clinical supply chains.
Pharmaceutical Technology
DECEMBER 6, 2023
The clinical trial market is in a state of flux; to navigate it, supply chain optimisation will be essential.
Pharma Times
DECEMBER 6, 2023
The commitments will make health systems faster, simpler and fairer for patients - News - PharmaTimes
Pharmaceutical Technology
DECEMBER 6, 2023
XmAb-662 is under clinical development by Xencor and currently in Phase I for Small-Cell Lung Cancer.
BioSpace
DECEMBER 6, 2023
Although looking for candidates on platforms like LinkedIn continues to be the norm, some headhunters are also combing Google Scholar and PubMed for authors with relevant skills.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Pharmaceutical Technology
DECEMBER 6, 2023
DB-1310 is under clinical development by Duality Biologics (Shanghai) and currently in Phase II for Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer).
Fierce Pharma
DECEMBER 6, 2023
After years of back and forth with Daiichi Sankyo over cancer drug patent claims, Novartis has thrown in the towel with a $182 million settlement. | In 2017, Daiichi's former subsidiary Plexxikon alleged that Novartis stepped on its Zelboraf patents with its GSK-acquired medicine Tafinlar. Many years later, Novartis is settling the case.
Pharmaceutical Technology
DECEMBER 6, 2023
XmAb-662 is under clinical development by Xencor and currently in Phase I for Cervical Cancer.
pharmaphorum
DECEMBER 6, 2023
Sanofi has deepened an existing collaboration with artificial intelligence specialist Aqemia in the latest among a flurry of collaborations between pharma companies and generative AI (genAI) companies. The French pharma group has signed a multi-year agreement with Paris-based Aqemia, focused on the discovery of small-molecule drug candidates across multiple therapeutic categories, through the application of genAI and deep physics algorithms that can model molecular interactions.
Advertisement
As the development pipeline for new drugs continues to grow, biopharmaceutical companies are re-evaluating how to best manage and balance resources across an increasing number of development projects and complex clinical trials. There are two approaches that can be used to speed a drug from development to clinic faster: timeline compression and parallel processing, but only one that considers the benefits of integrating clinical supply into the overall drug development process.
Expert insights. Personalized for you.
305 
Let's personalize your content